Semaglutide Weekly Injection Active Ingredient in Ozempic and Wegovy 15% Body Weight Reduction GLP-1 Receptor Agonist FDA Approved for Type 2 Diabetes (2017) and Weight Loss (2021) Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain Tirzepatide Weekly Injection Active Ingredient in Mounjaro 20% Body Weight reduction Dual GLP-1 and GIP Receptor Agonist FDA Approved for Type 2 Diabetes (2022) and on Fast-track for Weight Loss Approval in 2023 Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain These injections are GLP-1 medications that have been FDA-approved for Type 2 diabetes because of their ability to lower blood sugar and raise insulin levels
Shake, break, take: one bottle, one full serving, no fridge - pocket-sized for gym, desk or carry-on.
Astrocyte-neuron metabolic cooperation shapes brain activity
Circulating microRNA-23b as a New Biomarker for Rheumatoid Arthritis
That is the uncomfortable part
